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Abstract
Background: Exposure of macrophages to bacterial products such as lipopolysaccharide (LPS) results in
activation of the NF-κB transcription factor, which orchestrates a gene expression programme that
underpins the macrophage-dependent immune response. These changes include the induction or
repression of a wide range of genes that regulate inflammation, cell proliferation, migration and cell
survival. This process is tightly regulated and loss of control is associated with conditions such as septic
shock, inflammatory diseases and cancer. To study this response, it is important to have in vitro model
systems that reflect the behaviour of cells in vivo. In addition, it is necessary to understand the natural
differences that can occur between individuals. In this report, we have investigated and compared the LPS
response in macrophage derived cell lines and peripheral blood mononuclear cell (PBMC) derived
macrophages.
Results: Gene expression profiles were determined following LPS treatment of THP-1 cells for 1 and 4
hours. LPS significantly induced or repressed 72 out of 465 genes selected as being known or putative NF-
κB target genes, which exhibited 4 temporal patterns of expression. Results for 34 of these genes, including
several genes not previously identified as LPS target genes, were validated using real time PCR. A high
correlation between microarray and real time PCR data was found. Significantly, the LPS induced
expression profile of THP-1 cells, as determined using real time PCR, was found to be very similar to that
of human PBMC derived macrophages. Interestingly, some differences were observed in the LPS response
between the two donor PBMC macrophage populations. Surprisingly, we found that the LPS response in
U937 cells was dramatically different to both THP-1 and PBMC derived macrophages.
Conclusion: This study revealed a dynamic and diverse transcriptional response to LPS in macrophages,
involving both the induction and repression of gene expression in a time dependent manner. Moreover,
we demonstrated that the LPS induced transcriptional response in the THP-1 cell line is very similar to
primary PBMC derived macrophages. Therefore, THP-1 cells represent a good model system for studying
the mechanisms of LPS and NF-κB dependent gene expression.
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Primary human macrophages are sentinels of the immune
system and following infection, circulating monocytes
migrate from the peripheral blood to tissues where they
differentiate into resident tissue macrophages [1]. Recog-
nition of pathogen associated molecular patterns
(PAMPS), including gram negative bacterial lipolysaccha-
ride (LPS), results in activation of macrophages, leading
to a plethora of biological responses required for shaping
both the innate and adaptive arms of the immune
response [2]. These effects are mediated through the
release of chemokines and cytokines such as tumour
necrosis factor α (TNF) and interleukin 1β (IL-1). How-
ever, excess release of these mediators can result in septic
shock, multiple organ failure and acute respiratory dis-
tress syndrome [3]. Moreover, in mouse models of inflam-
mation induced cancer, including an LPS induced model
of lung metastasis, the release of cytokines by macro-
phages and host haematopoietic cells has been shown to
stimulate tumour cell growth [4,5].
Many of the signalling events leading to cytokine synthe-
sis and release following LPS exposure are now well estab-
lished. Binding of LPS to toll-like receptor 4 (TLR4)
activates two principal signalling pathways, distinguished
by their dependence on the adaptor molecules myeloid
differentiation factor 88 (MyD88) or TIR-domain-con-
taining adaptor inducing IFN-β (TRIF) [6-10]. Signifi-
cantly, both the Myd88 and TRIF pathways result in
activation of the transcription factor, nuclear factor κB
(NF-κB), a central regulator of the LPS, cytokine and stress
responses in many cell types, including macrophages
[8,9]. However, only the MyD88 independent, TRIF regu-
lated, pathway is involved in the activation of IFN-β and
interferon regulated genes such as CXCL10 via the tran-
scription factor IRF-3. Differential signalling through
MyD88 and TRIF results at least in part from the engage-
ment of distinct downstream signalling proteins [10].
The mammalian NF-κB family consists of five members,
RelA (p65), RelB, c-rel, p105/p50 (NFκB1) and p100/p52
(NFκB2) [11]. The NF-κB complex is composed of dimers
formed from these subunits and in unstimulated cells is
typically located in the cytoplasm bound to a member of
the IκB family of proteins, α, β and ε. All IκB's contain
ankyrin repeat, protein:protein interaction domains, a
feature shared with the p100 and p105 precursor proteins
which can also function in an IκB-like manner and retain
their NF-κB partner subunits in the cytoplasm [11].
Many inflammatory stimuli, including exposure to LPS,
TNF or IL-1, activate the canonical NF-κB signalling path-
way. This pathway is characterised by the rapid phospho-
rylation and subsequent ubiquitin dependent
degradation of IκBα by the 26S proteasome [11]. In some
cell types, this can be followed by phosphorylation and
degradation of IκBβ and ε, which contain analogous ser-
ine and lysine residues to those in IκBα required for phos-
phorylation induced ubiquitination. IκB phosphorylation
by this pathway requires the IκB kinase (IKK) complex.
This has three principal subunits, IKKα, β and the NF-κB
essential modulator protein, NEMO (also known as IKKγ)
[11]. Despite the high level of homology between IKKα
and IKKβ, phosphorylation of IκB proteins during canon-
ical pathway activation is performed almost exclusively by
IKKβ [11]. IKKβ is also required for the phosphorylation
and processing of the p105 subunit to p50 [12]. By con-
trast, IKKα is required for activation of the non-canonical
pathway, which is induced by a subset of NF-κB inducers
such as engagement of the CD40 and lymphotoxin-β
receptors, B-cell activating factor, LPS, BAFF ligand and
latent membrane protein (LMP)-1 of Epstein Barr virus
(EBV) [11,13]. The non-canonical pathway is dependent
on signalling through the NF-κB inducing kinase (NIK),
which results in the activation of IKKα homodimers and
the phosphorylation and 26S proteasome induced
processing of the p100 NF-κB subunit to p52 [13].
The study of the NF-κB response in macrophages has
often been limited to transformed cell lines. Such cell
lines offer many advantages in terms of ease of use and
can allow the biochemical dissection of many aspects of
NF-κB signalling. However, their transformed nature
might easily impact many aspects of NF-κB function,
which is strongly influenced by oncogenes and tumour
suppressors [12]. Indeed, differences in NF-κB signalling
between transformed and primary cells have previously
been noted [14]. Although primary human macrophages
can be readily cultured in vitro, their numbers and lifespan
are inherently limited. Furthermore, heterogeneity in
macrophage responses between donors is well docu-
mented and arises as macrophages differentiate from their
progenitors [15,16]. This can occur in part from genetic
variations. For example, TLR4 mutations in humans can
lead to decreased NF-κB DNA binding following LPS
exposure [17]. Two immortalised human monocyte/mac-
rophage cell lines commonly used by investigators to
study the LPS response at various stages in the monocyte/
macrophage differentiation process are U937 and THP-1
cells [18-21]. THP-1 cells have previously been shown to
be a reasonably accurate model for native monocyte
derived macrophages, as defined by an increase in adher-
ence and surface expression of macrophage specific mark-
ers following treatment with phorbol-12-myristate-13
acetate (PMA) [22-24]. In this study, using a focussed
microarray strategy and real-time PCR, we have character-
ised and compared the response to LPS in these cell lines
and human primary, peripheral blood mononuclear cell
(PBMC) derived macrophages. We find a surprisingly
close correlation between THP-1 cells and PBMC derivedPage 2 of 17
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κB response they provide a good model system for study-
ing LPS induced changes in gene expression.
Results
Analysis of LPS-induced gene expression in the THP-1 
macrophage cell line
Before analysis of LPS-induced changes in gene expression
in the THP-1 macrophage cell line could begin, it was first
necessary to characterise the NF-κB response in these cells.
Electrophoretic mobility shift analysis (EMSA) demon-
strated that LPS rapidly induces NF-κB DNA-binding. In
these and all subsequent experiments we did not differen-
tiate the THP-1 cells with PMA, as it is both an activator of
NF-κB [25] and has been shown to enhance levels of gene
expression in response to LPS [26]. This activity persists at
a high level for a number of hours before beginning to
decrease 12 hours after stimulation and being lost entirely
after 24 hours (Figure 1A). Supershift analysis demon-
strated that at both early and late time points this NF-κB
complex consisted primarily of the p50 and RelA subu-
nits, although some c-Rel could also be detected (Figure
1B). The presence of p52 and RelB was not analysed and
cannot be ruled out. To further clarify this response, IκB
protein levels were investigated. Rapid degradation and
resynthesis of IκBα was observed followed by a slower
loss of IκBβ and ε, consistent with previous reports (Figure
1C) [27,28]. It should be noted that the upper band in the
IκBε blot corresponds to a phosphorylated form and has
previously been detected using this antibody [28]. Con-
sistent with activation of the canonical NF-κB pathway, an
IKKβ inhibitor [29] blocked both IκB phosphorylation at
serine 32/36, degradation and induction of NF-κB DNA-
binding (data not shown).
Using this information, RNA was extracted from two sep-
arate batches of THP-1 cells, to create two biological rep-
licates, either stimulated with LPS for 1 or 4 hours or left
untreated. The two biological replicates were used to
ensure that any results were not biased by day-to-day var-
iation in RNA extraction [30,31]. The RNA was post-
labelled, ensuring both optimal yield of cDNA, random
attachment and equal labelling of samples [30,31].
To analyse LPS induced gene expression changes, we used
a highly focussed microarray containing PCR amplified
DNA fragments from genes with either predicted or
known NF-κB binding sites in their upstream sequences
[See Additional file 1]. These were identified either from a
previous review of NF-κB regulated genes [25] or from our
own analysis of the literature (Pubmed links for each gene
describing their association with NF-κB can be found in
the second sheet of Additional file 1). Also included were
genes without known κB elements but which belonged to
the same general gene families, such as chemokine genes
and their receptors. Such focussed arrays have previously
been used as an economical approach for detailed path-
way analysis of a carefully selected subset of genes [18].
Following labelling, samples were competitively hybrid-
ised to the arrays. Following hybridisation, normalisation
and data analysis, only genes with significant (p < 0.05),
as determined using the 1 sample T test, and with average
ratios of more than log2 1 or less than -1, were considered
as more than two fold up or down-regulated respectively
[see Additional file 2].
Using these criteria, 72 out of the 465 genes on the array
were found to significantly respond to LPS treatment in
THP-1 cells. These can be grouped into four temporal pat-
terns of expression (Figure 3). The most common patterns
were genes whose expression was unaffected after 1 hour
of LPS treatment but showed either a decrease (25 out of
72 genes) or an increase (19 out of 72 genes) 4 hours post-
treatment. The next most common pattern of expression
consisted of genes whose expression was induced follow-
ing 1 hour of LPS treatment and where, although fre-
quently still higher than in untreated cells, expression
decreased 4 hours post-treatment (18 out of 72 genes). 8
out of 72 genes exhibited a profile of being induced fol-
lowing 1 hour of LPS treatment with expression rising fur-
ther after 4 hours stimulation with LPS. The least common
pattern of expression were genes whose expression was
repressed following 1 hour LPS treatment but which
showed an increase in expression, relative to untreated
cells, after 4 hours (Fig 3). These 4 temporal patterns of
expression are consistent with previously reported obser-
vations in LPS treated, PMA differentiated THP-1 cells
[18,19].
Most genes responsive to LPS in THP-1 cells contain 
known or putative κB sites
The genes affected by LPS treatment can be further divided
into two different categories. Those that have been previ-
ously characterised as NF-κB target genes or which contain
putative κB sites in their upstream regulatory regions, as
determined by transcription factor prediction analysis
(Table 1, 47 out of the 72 genes), and those that do not
contain putative κB sites (Table 2, 25 out of the 72 genes)
[See also Additional file 1]. It cannot be ruled out that
there are genes in this latter category that contain cryptic
κB elements or where the NF-κB binding site is contained
in an intronic or remote enhancer motif. The number of
genes in the first category correlates with the observation
that, in B-cells, NF-κB is a master regulator of LPS
responses [32].
IRF-3 is a transcription factor that is induced in a TRIF-
dependent but MyD88 independent manner and is asso-
ciated with the induction of later LPS inducible genes [9].
Interestingly, most of the genes listed in Table 2 are onlyPage 3 of 17
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Effect of LPS on NF-κB DNA binding and IκB protein degradation in THP-1 cellsFigure 1
Effect of LPS on NF-κB DNA binding and IκB protein degradation in THP-1 cells. (A) THP-1 cells were treated 
with 2 µg/ml LPS for the times indicated. Nuclear extracts were prepared and assayed by EMSA with the HIV-1 κB probe. (B) 
Supershift analysis of the LPS induced NF-κB complex in THP-1 cells. (C) Effect of LPS on IκB degradation in THP-1 cells. THP-
1 cells were treated 2 µg/ml LPS for the times indicated. Whole cell extracts were prepared and blotted using antibodies spe-
cific for IκB-α, IκB-β and IκB-ε.
BMC Immunology 2007, 8:1 http://www.biomedcentral.com/1471-2172/8/1responsive to LPS at 4 hours (Figure 3). We therefore
searched for potential IRF-3 regulatory sites in these genes
by transcription factor prediction analysis and found that
many of these contain putative IRF-3 sites in their
upstream sequences, consistent with a potential role of
IRF-3 in their later LPS responsiveness (Table 2, indicated
by #, see also Additional File 1 for positions of sites).
Interestingly, RelA and IRF-3 interact following LPS treat-
ment and promote IRF-3 mediated transcription [33],
suggesting that these genes, albeit indirectly, might still be
regulated by NF-κB.
Validation of microarray results
Microarray data is subject to considerable variability, par-
ticularly with spotted microarrays from different laborato-
ries or among different platforms [34,35]. The four
temporal patterns of gene expression observed in this
study (Figure 3) have previously been observed [18,19].
However, among the individual genes some discrepancies
with previous reports are apparent, although these may
reflect the use of PMA differentiated THP-1 cells, for exam-
ple [18]. Therefore, it was necessary to validate the micro-
array results using another experimental approach.
Initially this was performed using semi-quantitative PCR
on a subset of the genes studied. This approach confirmed
both the four temporal patterns of expression and that
expression of CCL3, TNF-α and IL-1β, which differed
from that reported previously [18] was correct (Figure 4).
To obtain an accurate picture of differential gene regula-
tion and, importantly, to screen a larger number of genes
simultaneously, we next used a Taqman microfluidics,
Temporal patterns of gene expression in LPS stimulated THP-1 cellsFigure 2
Temporal patterns of gene expression in LPS stimulated THP-1 cells. Only genes with an average log2 ratio more 
than 1 or less then -1 at either 1 hour (Black line) or 4 hour (Red line) LPS time point relative to the control (P < 0.05, one-
sample t test) are shown. If genes had the ratio more than -1 or less then 1 for a particular time point, they were considered 
unchanged and their ratios were set to 0. Error bars represent the SEM. Data is representative of 8 microarray experiments, 2 
biological replicates and 2 technical replicates for each time point, and actual ratios for all genes in all replicates are presented 
in Additional file 2Page 5 of 17
(page number not for citation purposes)
BMC Immunology 2007, 8:1 http://www.biomedcentral.com/1471-2172/8/1real-time PCR based strategy. 34 of the genes identified in
the initial microarray screen were selected for inclusion on
the microfluidics cards for further validation. While simi-
lar patterns of gene expression were generally identified
between the microarray and real time PCR analysis, some
differences were observed (Table 3, see also Additional
File 2). In particular, because of the increased sensitivity
found with Taqman a greater fold change in gene expres-
sion is observed relative to the results obtained using
microarray. This is consistent with the previously reported
fold change bias in microarray experiments [36] and can
result in some genes being scored as no change in micro-
array but where a real difference in expression can be
observed using real time PCR. However, there were only
12 genes whose expression profile differed between the
two techniques. Out of these, 9 resulted from the reason
just described, while there were only 3 (JARID1B,
HLADRα and SMYD5) that were found to be false posi-
tives at both LPS time points (Table 3). Importantly, this
analysis confirmed the LPS responsiveness of the genes
CCL3L1, TXNIP, PDCD4, C-MYB, TOP2α, BUB1β and
ID2. These genes have not, to the best of our knowledge,
been previously identified as LPS responsive genes.
Comparison of gene expression in THP-1 cells to PBMC 
derived macrophages
In terms of expression of cell surface markers, PMA differ-
entiated THP-1 cells have previously been shown to be a
reasonably accurate model for native, monocyte derived,
macrophages [22]. Therefore, we next examined, at the
gene expression level, how the LPS responses of THP-1
cells and primary PBMC human macrophages compared.
First, EMSA confirmed that the PBMC macrophages we
isolated had low basal levels of NF-κB, which could be
strongly induced upon LPS treatment (Figure 4). Super-
shift analysis further demonstrated that this NF-κB com-
plex consisted primarily of RelA and p50 (Figure 4).
Although other complexes are visible, these were not char-
acterised further. Next, using Taqman microfluidics real-
time PCR, we analysed the expression of the 34 genes
investigated in THP-1 cells above. Broadly speaking there
was good agreement between the results obtained in THP-
1 cells and two separate donors of PBMC derived macro-
phages, although in a number of cases, CCL3, CCL4,
CXCL8, IL-1β, IL-1RN, COX-2, SOD2, BTG2 and IGFBP3,
while the genes were similarly induced or repressed there
were significant differences in relative fold induction
(Table 4). In addition, some genes, CCL22, CXCR4, IL-1β,
c-Myb, BTG2 and JARID1B, showed evidence of signifi-
cant donor to donor variability, although in many cases
the fold changes seen with these genes were low to begin
with. Only 4 genes, CCL22, PMAIP1, HLADRα and
SMYD5 showed significantly contrasting results between
THP-1 cells and both donor samples, although in these
latter two cases the fold changes were again small. Signif-
Validation of microarray results using semi-quantitative RT-PCRFigure 3
Validation of microarray results using semi-quantita-
tive RT-PCR. THP-1 cells were treated with 2 µg/ml LPS 
for 1 hour or 4 hours and RNA extracted. This was sub-
jected to semi-quantitative RT-PCR using primers specific for 
each of the genes shown. Data is representative of 3 inde-
pendent experiments. Experiments were performed on sepa-
rate days and GAPDH controls for each distinct experiment 
are shown.Page 6 of 17
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Table 1: Genes responsive to LPS that are known NF-κB targets or that have putative sites κB sites
Accession no Symbol Gene Name Reference
Chemokines and receptors
[genebank:NM_002983] CCL3 Chemokine, CC motif, Ligand 3 π [25]
[genebank:NM_002984] CCL4 Chemokine, CC motif, ligand 4 π [25]
[genebank:NM_005408] CCL13 Chemokine, CC motif, ligand 13 [68]
[genebank:NM_032964] CCL15 Chemokine, CC motif, ligand 15 [69]
[genebank:NM_006274] CCL19 Chemokine, CC motif, ligand 19 -1748*
[genebank:NM_002990] CCL22 Chemokine, CC motif, ligand 22 π [70]
[genebank:NM_001511] CXCL1 Chemokine CC motif, Ligand 1 π [25]
[genebank:NM_002089] CXCL2 Chemokine, CXC motif, ligand 2 π [25]
[genebank:NM_000584] CXCL8 Chemokine, CXC motif, ligand 8 π [25]
[genebank:NM_001565] CXCL10 Chemokine, CXC motif, ligand 10 [25]
[genebank:NM_005408] CXCL13 Chemokine, CXC motif, ligand 13 -1593*
[genebank:U28934] CCR2 Chemokine, CC motif, receptor 2 -1543*
[genebank:NM_003467] CXCR4 Chemokine, CXC motif, receptor 4 π [71]
Cytokines and Receptors
[genebank:NM_000594] TNF-α Tumour Necrosis Factor α π [25]
[genebank:NM_000576] IL1-β Interleukin 1 B π [25]
[genebank:NM_000577] IL1-RN Interleukin 1 receptor antagonist π [25]
[genebank:NM_005746] PBEF Pre B cell colony stimulating factor 1 π -533*, -479*
[genebank:NM_001250] TNFRSF5 TNF receptor superfamily, member 5 [72]
[genebank:NM_001561] TNFRSF9 TNF receptor superfamily member 9 [73]
[genebank:NM_005534] IFNGR2 Interferon, gamma receptor 2 -317, -220*, -144, -134*
Stress
[genebank:NM_000636] SOD2 Superoxide dismutase 2 πp [25]
[genebank:NM_000963] COX2 Cycloxygenase 2 π [25]
[genebank:NM_006427] TXNIP Thioredoxin interacting protein π -618
Apoptosis
[genebank:NM_015675] GADD45 β Growth arrest and DNA damage inducible gene GADD45, B π [74]
[genebank:NM_005879] TRIP Traf interacting protein -1736
[genebank:NM_006290] TNFAIP3 Tumour Necrosis factor α induced protein 3 π [25]
[genebank:NM_001165] cIAP2 Cellular inhibitor of apoptosis 2 π [75]
Transcription
[genebank:NM_020529] IκB-α Inhibitor of κlight chain gene enhancer in B cells; α π [25]
[genebank:NM_003998] NFκB1 Nuclear factor of κB, subunit 1 π [25]
[genebank:NM_002908] C-REL V-rel avain reticuloendotheliosis viral oncogene homolog; rel π [25]
[genebank:NM_005375] C-MYB V-MYB avian myeloblastosis viral oncogene homolog π [25]
[genebank:NM_004364] CEBPα CAAT/enhancer binding protein α [25]
[genebank:U96131] TRIP13 Thyroid hormone interactor 13 -1611, -1601*, -1600* -1464*
[genebank:NM_002129] HMGB2 High mobility group box 2 -1531, -1520, -1087
Cell Cycle/Differentiation
[genebank:NM_006763] BTG2 B-cell translocation gene 2 π [76]
[genebank:NM_002166] ID2 Inhibitor of DNA binding 2 π -571*, -174
[genebank:X54941] CKS1B CDC28 protein kinase 1B -1416, -1406* -717, -647, -637*, -646 -636*
[genebank:NM_004701] CCNB2 Cyclin B2 -1387
Growth
[genebank:NM_000598] IGFBP3 Insulin-like growth-factor binding protein 3 π -1729
Miscellaneous
[genebank:NM_000674] ADORA1 Adenosine A1 receptor [25]
[genebank:NM_000201] ICAM1 Intracellular adhesion molecule 1 π [25]
[genebank:NM_002421] MMP1 Matrix metalloproteinase 1 [25]
[genebank:X13895] SAA3P Serum amyloid A3 pseudogene -1790*
[genebank:NM_002291] LAMβ1 Laminin, β 1 -263, -253
[genebank:NM_004119] FLT3 FMS related tyrosine kinase 3 -295, -285*
[genebank:NM_001365] DLG4 Discs, large homolog 4 -1425, -1415*, -544*
[genebank:M22001] F13A1 Coagulation factor X111, A1 polypeptide -404, -72*
LPS responsive genes that have been shown to be NF-κB targets (Reference is indicated) or contain putative κB sites. The position of the site in 
relation to the initiator ATG is indicated and * indicates the site is found on the reverse strand. π indicates genes validated using real time PCR.
BMC Immunology 2007, 8:1 http://www.biomedcentral.com/1471-2172/8/1icantly, these results confirmed that the novel LPS respon-
sive genes CCL3L1, PDCD4, TOP2α, BUB1β and ID2
identified in THP-1 cells, exhibit an almost identical
expression profile to primary human macrophages.
Comparison of gene expression in U937 cells to PBMC 
derived macrophages
The U937 cell line, which like THP-1 cells have previously
been shown to express TLR4, irrespective of differentia-
tion status [21], is also a frequently used cell line to study
the LPS response [22-24]. We therefore also determined
the expression profile of the same set of 34 genes using
real time PCR in this cell type. Surprisingly, we found that
in contrast to THP-1 cells and PBMC derived macro-
phages, LPS mediated gene expression in U937 cells is
very different. Most of the genes tested were not respon-
sive to LPS or were induced at very low levels (Table 4).
Only 7 genes, CXCL2, TNF-α, cIAP2, SOD2, TNFAIP3,
IκB-α and ICAM1, showed an identical expression profile
between THP-1 cells, U937 cells and PBMC derived mac-
rophages from both donors (Table 4). None of the novel
LPS responsive genes in THP-1 cells and PBMC derived
macrophages described above are expressed in U937 cells
following LPS treatment.
Discussion
In this report we have characterised the LPS response in
macrophages and macrophage cell lines. Strikingly, we
observed that although THP1 cells are transformed and
immortalised, their LPS induced gene expression signa-
ture remains very similar to primary macrophages. Inter-
estingly, there was also some heterogeneity between the
two different PBMC donor samples. This donor-to-donor
variation is not really surprising since macrophage heter-
ogeneity occurs through a developmental mechanism as
they differentiate and is likely to be important for the gen-
eration of diversity in the immune response [15]. For
example, different populations of macrophages have been
shown to exhibit different methylation patterns and this
has been implicated in modulating the LPS response
[37,38]. Moreover, even different sub-clones of RAW264
macrophages have been reported to respond differently to
Table 2: Genes responsive to LPS that do not contain putative κB in their upstream sequences
Accession No Symbol Gene Name
Chemokines and receptors
[genebank:NM_021006] CCL3L1 Chemokine, CC motif, ligand 3-like protein 1 π #
[genebank:NM_002988] CCL18 Chemokine, CC motif, ligand 18
[genebank:NM_005623] CCL8 Chemokine, CC motif, ligand 8 π #
[genebank:NM_002991] CCL24 Chemokine, CC motif, ligand 24 #
[genebank:NM_001838] CCR7 Chemokine, CC motif, receptor 7 #
[genebank:NM_002620] PF4V1 Platlet Factor 4, variant 1
Angiogenesis
[genebank:NM_003246] THBS1 Thrombospondin 1 #
[genebank:NM_012484] HMMR Hyaluronan-mediated motility receptor #
Cytokines and Receptors
[genebank:NM_003853] IL18 RAP Interleukin 18 receptor accessory protein #
[genebank:NM_000565] IL6R Interleukin 6 receptor #
Apoptosis
[genebank:U75285] AIP4 Apoptosis inhibitor 4 (survivin)
[genebank:NM_021127] PMAIP1 Phorbol 12 myristate 13 acetate induced protein 1 *#
[genebank:NM_014456] PDC4 Programmed cell death 4 π
[genebank:X75252] PBP Prostatic binding protein #
Transcription
[genebank:NM_001211] BUB1β Budding uninhibited by benzimidazoles 1, S. Cerevisiae homolog of B π#
[genebank:X52317] H2FAZ H2A histone family member Z
[genebank:NM_002128] HMGB1 High mobility group box 1
[genebank:NM_006618] JARID1B Jumonji, AT-rich interactive domain 1B π #
[genebank:NM_006347] PPIH Peptidyl-prolyl isomerase H #
[genebank:NM_005030] PLK1 Polo-like kinase #
[genebank:NM_001067] TOP2a Topoisomerase, DNA, 11, α π
Growth
[genebank:NM_000222] KIT v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog
Miscellaneous
[genebank:NM_019111] HLADRα Major histocompatibilty complex, class II, DR α π
[genebank:D14657] K1AA0247 #
[genebank:NM_006062] SMYD5 SMYD family member 5 π
π Indicates those genes validated using real time PCR. # Indicates those genes that contain putative IRF-3 sites [see Additional file 1 for position].Page 8 of 17
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although NF-κB is a master regulator of the LPS response
[32], other factors such as the chromatin structure of gene
promoters will influence whether transcription initiation
occurs. Indeed, following LPS treatment, a subset of genes
exist which require chromatin remodelling events to
allow access of NF-κB and the RNA polymerase II machin-
ery to their promoters at later time points [39,40].
By contrast with the results from THP1 cells and PBMCs,
the U937 cell line showed dramatic differences in the gene
expression changes induced in response to LPS treatment.
This may reflect differences in the differentiation status of
these cells or epigenetic differences in the chromatin struc-
ture at the promoter levels of these genes. For example,
differentiation has been shown to increase expression of
CD14, an LPS receptor [23,41,42] but in this study both
the THP-1 and U937 cells were not treated with differen-
tiating agents (such as PMA) prior to LPS stimulation.
Therefore, these differences may reflect differing levels of
CD14 cell surface expression. Alternatively, these results
might reflect clonal variations between U937 cells used in
different laboratories.
In other systems, the LPS response has been shown to
depend almost entirely on the initial activation of the NF-
Effect of LPS on NF-κB DNA binding in PBMC derived macrophagesFigure 4
Effect of LPS on NF-κB DNA binding in PBMC derived macrophages. (A) PBMC derived macrophages were isolated 
and were treated with 2 µg/ml LPS. Nuclear extracts were prepared and assayed using EMSA with the HIV-1 probe (A). (B) 
Supershift analysis of the LPS induced NF-κB complex in PBMC derived macrophages.Page 9 of 17
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Table 3: Comparison of microarray and real time PCR data
Microarray Taqman
Gene 1 hr LPS 4 hr LPS 1 hr LPS 4 hr LPS
Chemokines and receptors
CCL3 5.744 2.200 1622 (± 322) 141 (± 27)
CCL3L1 5.708 2.603 56 (± 3) 4 (± 1)
CCL4 4.769 3.399 7047 (± 836) 2481 (± 714)
CCL8 * 1.859 NC 8 (± 2) 94 (± 38)
CCL22 NC 4.021 NC 135 (± 28)
CXCL1 * 1.272 NC 258 (± 41) 250 (± 21)
CXCL2 3.938 2.787 243 (± 85) 68 (± 13)
CXCL8 * NC 1.957 1016 (± 57) 491 (± 56)
CXCR4 NC -1.493 NC -4 (± 1)
Cytokines and receptors
IL-1β 4.649 4.289 3490 (± 254) 1891 (± 135)
IL-1RN * NC 1.830 4 6 (± 2)
PBEF 1.008 3.029 5 (± 2) 19 (± 1)
TNF-α 4.808 2.116 392 (± 55) 39 (± 4)
Stress
COX-2 3.673 1.333 166 (± 34) 29 (± 8)
SOD2 4.433 5.620 44 (± 7) 264 (± 37)
TXNIP -3.757 -1.638 -11 (± 2) -2 (± 1)
Apoptosis
cIAP2 * NC 1.151 19 (± 3) 112 (± 11)
GADD45β 1.212 1.323 7 (± 1) 8 (± 1)
PDCD4 NC -1.048 NC -7 (± 1)
PMAIP1 2.604 NC 7 (± 1) NC
TNFAIP3 2.905 2.526 104 (± 17) 44 (± 8)
Transcription
C-MYB NC -1.584 NC -5 (± 1)
TOP2α NC -1.561 NC -3
C-REL * NC 2.869 4 (± 1) 38 (± 3)
IκB-α 4.024 3.006 40 (± 4) 19 (± 2)
NFκB1 1.150 3.427 4 (± 1) 36 (± 2)
Cell cycle and Differentiation
BTG2 * 2.023 NC 116 (± 21) 32 (± 7)
BUB1β NC -1.244 NC -3
ID2 NC 1.299 NC 4 (± 1)
JARID1B π 2.675 4.061 NC NC
Growth
IGFBP3 * NC 4.182 43 (± 9) 1420 (± 167)
Adhesion
ICAM1 * NC 1.188 6 70 (± 44)
Miscellaneous
HLA-DRα π NC 1.593 NC NC
SMYD5 π 3.699 2.417 NC NC
Real time PCR results correspond to mean fold change normalised to GAPDH from 3 biological replicates and SEM is indicated. Genes where 
significantly different results between microarray and Taqman data was observed are indicated with an π. Genes which were originally scored as no 
change (NC) based on microarray data (at one time point) but where the increased sensitivity of Taqman revealed a change are indicated with an *. 
Note, any gene that showed a mean fold change between 2 and -2 was scored as NC in Taqman.
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Table 4: Comparison of LPS response in U937 cells, THP-1 and PBMC macrophages.
PBMC macrophage
U937 THP-1 Donor A Donor B
Time of LPS treatment
Gene 1 4 1 4 1 4 1 4
Chemokines/Receptors
CCL3 18 19 (± 3) 1622 (± 322) 141 (± 27) 22 57 90 89
CCL3L1 ND 21 (± 7) 56 (± 3) 4 (± 1) 62 51 271 83
CCL4 30 (± 11) 228 (± 63) 7047 (± 836) 2481 (± 714) 31 154 197 445
CCL8 ND ND 8 (± 2) 94 (± 38) 11 134 42 175
CCL22 NC NC NC 135 (± 28) NC 3 NC NC
CXCL1 ND ND 258 (± 41) 250 (± 21) 74 86 308 91
CXCL2 * 15 (± 3) 8 (± 3) 243 (± 85) 68 (± 13) 97 35 260 16
CXCL8 7 (± 1) 9 (± 3) 1016 (± 57) 491 (± 56) 118 280 282 178
CXCR4 NC NC NC -4 (± 1) 2 NC 2 -4
Cytokines/Receptors
IL-1β 5 6 (± 1) 3490 (± 254) 1891 (± 135) 139 277 905 325
IL-1RN NC NC 4 6 (± 2) 11 56 21 75
PBEF NC 2 5 (± 2) 19 (± 1) 2 24 2 37
TNF-α* 9 (± 2) 3 392 (± 55) 39 (± 4) 164 144 626 233
Stress
COX-2 14 (± 4) 17 (± 5) 166 (± 34) 29 (± 8) 291 888 432 333
SOD2 * 2 7 44 (± 7) 264 (± 37) 6 42 7 31
TXNIP NC NC -11 (± 2) -2 (± 1) -3 -2 -3 -3
Apoptosis
cIAP2 * 6 (± 1) 12 19 (± 3) 112 (± 11) 11 54 16 26
GADD45β NC NC 7 (± 1) 8 (± 1) 4 18 10 24
PDCD4 NC NC NC -7 (± 1) NC -2 NC -3
PMAIP1 NC NC 7 (± 1) NC 127 74 213 34
TNFAIP3 * 17 (± 1) 15 (± 3) 104 (± 17) 44 (± 8) 54 63 83 39
Transcription
C-MYB NC NC NC -5 (± 1) NC NC -2 3
TOP2α NC NC NC -3 NC -3 NC -2
C-REL NC NC 4 (± 1) 38 (± 3) 2 15 3 8
IκB-α* 8 (± 2) 6 40 (± 4) 19 (± 2) 18 17 20 16
NFκB1 NC 2 4 (± 1) 36 (± 2) 3 35 4 27
Cell cycle/Differentiation
BTG2 4 (± 1) 5 (± 2) 116 (± 21) 32 (± 7) 5 3 8 NC
BUB1β NC NC NC -3 NC -5 NC -4
ID2 NC NC NC 4 (± 1) NC 2 NC 2
JARID1B NC NC NC NC NC 2 NC NC
Growth
IGFBP3 ND ND 43 (± 9) 1420 (± 167) ND 12 ND 46
Adhesion
ICAM1 * 2 5 (± 1) 6 70 (± 44) 7 19 10 20
Miscellaneous
HLA-DRα 2 (± 4) NC NC NC NC 2 NC 2
SMYD5 NC NC NC NC NC -2 NC -2
Real time PCR results correspond to mean fold change normalised to GAPDH from 3 biological replicates of U937 cells treated with LPS and SEM 
is indicated. Genes showing an identical expression profile between THP-1 cells, U937 cells and PBMC derived macrophages from both donors are 
indicated with an *
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IKK inhibitor [29] confirmed that the expression of
almost all the genes validated by real-time PCR are NF-κB/
IKK-dependent (data not shown). However, it cannot be
concluded that all these genes are direct NF-κB targets.
Although many of these genes contain known or putative
NF-κB sites in their promoters, many others do not
(Tables 1 &2) and may therefore be targets of transcrip-
tion factors, such as AP-1 or IRF-3, activated as a second-
ary consequence of the initial wave of NF-κB induction
[9,32]. A recent study using a ChIP-on-chip approach
identified hundreds of direct NF-κB targets following LPS
stimulation of U937 cells [24]. Interestingly, 157 genes
were bound by NF-κB subunits prior to LPS treatment,
and after 1 hour of LPS stimulation this increased to 326
genes. Importantly, in the unstimulated cells, it was the
p50 NF-κB subunit that bound these promoters and RelA
recruitment was only observed following LPS treatment
[24]. Among the promoters demonstrated to recruit RelA
were those for the CCL3, CCL4, ICAM1, IL-1β, CXCL8 and
TNF-α genes [24], all of which we also found to upregu-
lated following 1 hour of LPS treatment. However, in con-
trast to this study, we found no upregulation of GADD45β
or PMAIP1 expression in U937 cells, although these genes
were demonstrated to recruit RelA following LPS treat-
ment [24]. This may be related to the differences of exper-
imental conditions, such as serotype of LPS. It should also
be noted that some commonly used commercial prepara-
tions of LPS can contain other, contaminating, bacterial
products such as peptidoglycans and RNA [43]. These can
lead to signalling through TLR2 in addition to TLR4 [43]
and we cannot rule out that our results might reflect the
activation of such additional signalling pathways.
In addition to inflammatory mediators, LPS induced
genes with a wide variety of different functions. These
included genes associated with cell stress (SOD2, TXNIP),
apoptosis (GADD45β, cIAP2, TNFAIP3), the cell cycle and
differentiation (BTG2, ID2). In addition, the products of
many genes have the potential to be involved in feedback
loops. For example, inflammatory molecules such as TNF-
α, IL-1β and CCL19 have been shown to promote NF-κB
signalling [44-46]. Excessive release of cytokines is associ-
ated with the adverse clinical consequences of infection
such as sepsis and shock [3]. Therefore, it was of interest
to also find a plethora of LPS responsive genes that can
limit feedback signalling. IL-1RN is a protein that binds to
the IL-1R, inhibiting binding of IL-1β and thus neutralis-
ing the biological activity of this cytokine [47]. The anti-
apoptotic gene TNFAIP3 is involved in the termination of
TLR-induced NF-κB activity and pro-inflammatory gene
expression, in macrophages, and protects against endo-
toxin shock [48]. The pro-apoptotic gene PBP can also
interact with upstream components of the NF-κB signal-
ling pathway, including NIK, MEKK1 and TAK1 [11], and
therefore inhibits NF-κB activation induced by TNF-α and
IL-1β [49]. Furthermore, similar to PBP, the pro-apoptotic
gene TRIP also inhibits NF-κB signalling [50].
It is also of interest, that many genes associated with an
anti-apoptotic response such as TNFAIP3, GADD45β,
cIAP2 [48,51,52] were induced by LPS whereas those
genes that are associated with being pro-apoptotic, such as
PBP, PDCD4 [53,54], were repressed. This also correlates
with the later co-expression of CCL19 and its receptor
CCR-7, which has been shown to promote NF-κB signal-
ling and an anti-apoptotic response [46]. Indeed, delayed
apoptosis observed in patients with bacterial sepsis has
been reported to correlate with expression of the cytokine
PBEF [55], which we find to be expressed in response to
LPS. Although these results are consistent with the widely
reported anti-apoptotic effects of NF-κB [56], it is interest-
ing to note that some well known anti-apoptotic target
genes, such as Bcl-xL, were not significantly induced by
LPS in THP-1 cells [see Additional file 2].
Conclusion
Although this study examined only a limited set of genes
a number of discoveries were made and some significant
conclusions can be drawn. Firstly, the temporal nature of
LPS induced gene expression allowed four distinct pat-
terns of gene expression to be defined. Additional time-
points may reveal further subtleties but it is clear that the
changes in gene expression following LPS stimulation are
dynamic and feature both the time-specific repression as
well as activation of gene expression. However, it should
be noted that gene expression patterns do not necessarily
correlate with protein levels [57]. This analysis also
allowed us to conclude that THP-1 cells provide a much
better model system for evaluating the LPS response in
macrophages than U937 cells: relatively few differences
were observed between THP-1 cells and primary macro-
phages. These included a number of novel LPS-responsive
genes identified in this study, CCL3L1, TXNIP, PDCD4, C-
MYB, TOP2α, BUB1β and ID2,. Inhibitors of the NF-κB/
IKK pathway have many potential uses, including the
treatment of inflammatory diseases, such as rheumatoid
arthritis and cancer. In many of these diseases, cytokine
and chemokine production by macrophages have been
shown to play a key pathological role [4,5]. While analysis
of primary macrophages in culture will always provide
more physiologically relevant information than cultured
cell lines, it is also the case that primary cells are hard to
culture for long periods and in the quantities required to
permit biochemical analysis. The confirmation here that,
in many respects, THP-1 cells are a valid model system for
studying the LPS response in macrophages, will therefore
give confidence that the conclusions drawn from such
studies can be applied in vivo.Page 12 of 17
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Cell lines
THP-1 and U937 cells were cultured in RPMI 1640
medium supplemented with 10% heat inactivated foetal
calf serum (FCS), 1% Penicillin and Streptomycin and 5
mM Glutamine (PSG) at 37°C, 5% CO2. For cell treat-
ment, 1 × 107 cells were treated with 2 µg/ml LPS 0111:B4
(Sigma, cat no L4391, purified by phenol extraction and
gel filtration) for the appropriate times.
Isolation and culture of PBMC derived macrophages
Buffy coat preparations used were all transported at room
temperature and were 1 day old (to allow time for testing
for HIV and HepC). 80–100 ml of buffy coat (Ninewells
Blood Transfusion Service, Dundee) was diluted to a final
volume of 250 ml, with room temperature PBS supple-
mented with 10 mM glucose and 5 mM EDTA. 30 ml was
layered onto 15 ml of Ficoll and peripheral blood mono-
nuclear cells (PBMCs) were isolated by density centriguga-
tion according to the manufacturers instructions
(Amersham). Monocytes were isolated from PBMCs by
adherence, as described previously [58]. Briefly, 1.5 × 108
PBMCs, resuspended in 10 mls of 37°C RPMI supple-
mented with 10% heat inactivated FCS and 1% PSG, were
plated in tissue culture dishes and placed in a 37°C incu-
bator for 1 hour to allow adherence to take place. Non-
adherent cells were removed by gentle re-suspension and
adherent cells were washed quickly, but gently, in 37°C
media, until no free-floating cells were observed using
light microscopy. Washing was repeated a total of 4 times,
followed by a 20 minute incubation at 37°C to prevent
monocyte loss during the washing steps. The cells were
then washed a further 4 times, until a homogenous popu-
lation of monocytes was detected by light microscopy.
Following overnight culture, media was replaced by
media supplemented with 10 ng/ml macrophage colony
stimulating factor (M-CSF, Sigma). Cells were cultured for
7 days with fresh addition of media/M-CSF every couple
of days. Isolation and culture of PBMC derived macro-
phages from both donors was conducted at the same time.
Western Blot analysis
After treatment, THP-1 cells were washed once with cold
PBS, solubilized by resuspending the pellet in ice cold
whole cell extract buffer (20 mM Hepes pH 7.6, 400 mM
NaCl, 1 mM EDTA, 5 mM NaF, 500 µM Na3VO4, 25%
glycerol, 0.1% NP-40, 1 mM PMSF, 1 mM DTT, 0.1 mg/ml
aprotonin) and passed through a 25G needle 10 times, as
described [59]. Lysates were centrifuged at 14,000 rpm for
15 minutes. 25 µg of supernatant was separated by elec-
trophoresis on a 10% SDS polyacrylamide gel and trans-
ferred to polyvinylidene difluoride (PVDF) membranes.
Antibodies specific for IκB-α, IκB-β, IκB-ε were kindly
donated by Dr Nancy Rice (NCI, USA) and used at dilu-
tions of 1:1000. Anti-Sera directed against β-actin were
obtained from Cell Signalling and used at 1:2000 dilu-
tion. Immunoreactive proteins were detected by enhanced
chemiluminescent protocol (Amersham).
Electrophoretic Mobility Shift Assay (EMSA)
After treatment, nuclear extracts were prepared by washing
cells once with cold PBS, resuspending the cell pellet in ice
cold low salt buffer (10 mM Hepes pH 7.9, 1.5 mM
MgCl2, 10 mM KCl, 1 mM DTT, 1 mM PMSF, 1 µg/ml leu-
pepetin, 1 µg/ml aprotonin, 1 µg/ml pepstatin, 1 µg/ml
E64) and passed through a 25G needle 10 times, as
described [59]. Lysates were centrifuged at 14,000 rpm for
10 minutes and the cytoplasmic fraction was removed.
The nuclear pellets were resuspended in high salt buffer
(20 mM Hepes pH 7.9, 1.5 mM MgCl2, 420 mM NaCl, 1
mM DTT, 1 mM PMSF, 1 µg/ml leupepetin, 1 µg/ml apro-
tonin, 1 µg/ml pepstatin, 1 µg/ml E64, 25% glycerol),
rocked at 4°C for 15 minutes and centrifuged at 14,000
rpm, for 15 minutes. Supernatants were removed and
stored at -80°C prior to running the EMSA. 10 µg of
nuclear extract was used in each EMSA reaction using a
synthetic double stranded 32P end labelled probe contain-
ing the NF-κB binding site of the HIV-1 LTR
(5'GATCCGCTGGGGACTTTCCAGCGC3'). For the bind-
ing assay, nuclear extract was added to 20 mM Hepes
pH7.9, 125 mM NaCl, 1 mM DTT, 1 µg of poly(dI-dC)
and 0.1 ng probe and incubated at room temperature for
15 minutes. For supershift assays 0.5 µl of anti-sera
against RelA, p50 or c-Rel or control IgG antibody were
added before addition of the probe. Samples were sepa-
rated on a pre-run nondenaturing polyacrylamide gel in
TGE buffer (25 mM Tris-HCl pH8.0, 190 mM glycine, 1
mM EDTA) for 4 hours at 150V. The gel was dried and NF-
κB DNA binding was visualised by autoradiography.
Microarray printing, labelling and hybridisation
A total of 465 PCR-amplified cDNA clone fragments were
obtained from AstraZeneca, dissolved in 3xSSC printing
buffer and printed in triplicate onto Corning GAPS II
Coated Slides (Corning Life Sciences, Corning, NY, USA).
Printed arrays were processed and stored according to the
slide manufacturer's instructions. Total RNA was labelled
with CyScribe Post Labelling Kit (Amersham) as recom-
mended by the manufacturer's protocol, except that syn-
thesized cDNA was purified by ethanol precipitation and
the labelled target was purified with QIAquick PCR Purifi-
cation Kit (QIAGEN). Microarray pre-hybridization,
hybridization and washes were performed according to
protocols and conditions previously described [60],
except that the hybridization buffer contained 50% for-
mamide, 5% dextrane sulfate, 5× Denhardt's solution, 3×
SSC, 1% SDS, and all washes were done at room temper-
ature. Each experiment was performed in two biological
replicates, with two technical (dye-swap) replicates for
each.Page 13 of 17
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Microarrays were scanned using an ArrayWoRxe scanner
and images were analysed with ArrayWoRx Software
(Applied Precision LLC). Raw spot intensity data were
imported in locally installed BASE [61] and pre-processed
by local background subtraction, quality filtering (SNR >
3), spot averaging and calculating raw experiment/control
ratios. Tables with ratios for spots with two or more exper-
imental replicates were imported into and analysed with
locally installed TIGR Multiexperimental Viewer (TMeV)
software package [62]. First, data were adjusted by log2-
transformation and global median normalization. Then,
differentially expressed genes between experimental and
control conditions were determined with one-sample t-
test (P < 0.05, > 2-fold change). Selected genes were anno-
tated using public databases and additional literature
search. The microarray data have been deposited in
ArrayExpress (accession no: E-MEXP-868) [63].
Real time quantitative PCR
After treatment, total RNA was extracted from THP-1 cells
using the RNeasy Mini Kit (QIAGEN) according to the
manufacturers instructions, which included a DNase step.
Purified RNA was quantified and assayed for degradation
using an agilent bioanalyzer (Agilent) according to the
manufacturers instructions. 125 ng of total RNA was used
to determine gene expression levels by Taqman analysis
using the ABI PRISM 7900HT sequence detection system.
For analysis, a threshold was set for the change in fluores-
cence at a point in the linear PCR amplification phase. The
level of RNA for treated cells compared to untreated cells
and normalised to GAPDH was calculated using the SDS
2.1 software (Applied Biosystems) which relies on the
comparative Ct method of quantification ()[64]. Genes
that exhibited a mean fold change between 2 and -2 were
considered to be unaffected. Human primers and probes
specific for each of the genes and housekeepers were
obtained as assay on demands on microfludic cards [65].
Cycling conditions were set at 35 cycles of 50°C for 30
min, 94.5°C for 15 min, 97°C for 30 seconds and 59.7°C
for 1 minute.
Semi-quantitative PCR
Semi-quantitative RT-PCR was carried out using the
AccessQuick™ RT-PCR system according to the manufac-
turers instructions (Promega). Briefly, 10–100 ng of RNA
was added to a tube containing 1 × reaction buffer, 50
pmol primers and 5U AMV reverse transcriptase in a final
volume of 50 µl. Cycling conditions were 48°C for 45
minutes, 94°C for 2 minutes, then 40 cycles of 94°C for 1
minute, 60°C for 1 minute, 68°C for 2 minutes and 1
cycle of 68°C for 5 minutes. Human gene specific primer
sequences used were; SOD2 forward
(5'CAGATCATGCAGCTGCACCAC3'), reverse
(5'GTAGTAAGCGTGCTCCCACAC3'); IL-1β forward
(5'GCCATGGACAAGCTGAGGAAG3'), reverse
(5'GTGCTGATGTACCAGTTGGG3'); TNF-α forward
(5'GCGTGGAGCTGAGAGATAACC3'), reverse (5'
GATCCCAAAGTAGACCTGCCC3'); TXNIP forward
(5'CTATCCTGGGCTGCAACATCC3'), reverse (5'
GTTGAGGATGCAGGGATCCAC3'); CCL3 forward (5'
CTTGCTGTCCTCCTCTGCAC3'), reverse
(5'TCACTGGGGTCAGCACAGAC3'); C-MYB forward (5'
ACTTCCACCCCCCTCATTGG3'), reverse
(5'GCTCCTCCATCTTTCCACAGG3'); ID2 forward
(5'GAAAGCCTTCAGTCCCGTGAG3'), reverse (5'
TCCGTGTTGAGGGTGGTCAG3'); BTG2 forward
(5'GGAAGGGAACCGACATGCTC3'), reverse
(5'CTAGCTGGAGACTGCCATCAC3') and GAPDH for-
ward (5'GGTCGTATTGGGCGCCTGGTCACC3'), reverse
(5'CACACCCATGACGAACATGGGGGC3')
Identification of NF-κB and IRF-3 promoter binding sites
NF-κB binding sites were identified as previously
described [66]. 2 Kb of genomic sequence upstream from
the initiator ATG codon of each gene on the array was
determined [see Additional File 1]. This sequence was
analysed with Gene Runner software (Hastings Software,
Hastings on Hudson, NY, USA) to search for the κB motif
5'GGGRNNYYCC3' [66]. The same sequence was used to
search for the IRF-3 motif 5'GAAANNGAAANN3' [67].
Data deposition
The microarray data have been deposited in ArrayExpress
(accession no: E-MEXP-868) [63]
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